Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Personen
Suche
EN
Alle Personen
Patricia Pozo-Rosich
Sortiert nach Typ
Datum
Invited speaker
Invited lecture
Therapy with devices: myth
Vortrag
ePoster
P023
Effectiveness of galcanezumab versus traditional oral migraine preventive medications: 3-month findings from the TRIUMPH observational study
ePoster
LP055
Post hoc analysis of the APPRAISE study: Evaluating treatment satisfaction and quality of life improvement in patients with episodic migraine-erenumab vs standard of care
Weitere Beteiligungen
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
ePoster
P090
Subarachnoid Aneurysmal Hemorrhage & migraine: prevalence, characteristics and risk of developing acute and persistent headache
ePoster
P021
Predictors of ≥50% and ≥75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
ePoster
P023
Effectiveness of galcanezumab versus traditional oral migraine preventive medications: 3-month findings from the TRIUMPH observational study
ePoster
P112
Design of the ContemporAry ProspecTive Understanding of migraine Real-world Evidence (CAPTURE) study
ePoster
P026
Effectiveness of galcanezumab vs. traditional oral migraine preventive medications: 3-month results from Real-World TRIUMPH study for Europe [Germany, Italy, Spain, and the United Kingdom]
ePoster
P029
Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
ePoster
P031
Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
ePoster
P158
Efficacy and safety of onabotulinumtoxinA in pediatric patients with chronic migraine
ePoster
LP066
Resting-state EEG power analysis in patients with chronic and high-frequency episodic migraine
ePoster
P017
Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL study
ePoster
LP055
Post hoc analysis of the APPRAISE study: Evaluating treatment satisfaction and quality of life improvement in patients with episodic migraine-erenumab vs standard of care
ePoster
P246
Migraine in patients with preeclampsia: prevalence and correlation with angiogenic factors
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz